Four non-medical broken vial US complaints for Gammagard Liquid were discovered in April.
Inspection Record
Baxalta Belgium Manufacturing S.A. — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Quality Investigations were not conducted per SOP-2024-Adverse Event Quality Investigations.
There is a failure to thoroughly review a batch or any of its components to meet any of its specifications Whether or not the batch has been already distributed.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Microvascular Tissue, Inc2025-04-08 · US FDASimilar to finding 3 There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been…
- TEVA Animal Health2015-07-24 · US FDASimilar to finding 3 There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been…
A record as of the US FDA document published on 2026-10-27. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.